Genomic Testing for NSCLC Used Less Frequently in Community-based Practices

Recommended genomic profiling for EGFR and ALK for patients with non-small cell lung cancer appeared under-used at community-based practices, according to published findings. “The guidelines recommend broad genomic testing in all patients with advanced non-small cell lung cancer, but adherence is often impractical in the community setting because of the challenges of working with small tissue biopsies,” said Martin E. Gutierrez, M.D., director of the Drug Discovery and Phase 1 Unit at John Theurer Cancer.

Read full article on